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66-70 Gy : gross tumor volume + isotropic expansion of 5 mm 
; CTV 59.4-60 Gy: lymph node regions (LNR) at high risk; 
CTV50.4-54 Gy: LNR at low risk. PTV were developed by 
adding to CTV an isotropic expansion of 5 mm. Patients with 
II stage NPC were treated with concurrent CHRT and patient 
with III-IVA/B stage were treated with neoadjuvant CHT 
followed by concurrent CHRT. Acute and late toxicities were 
graded according to Radiation Therapy Oncology 
Group/European Organisation for Research and Treatment of 
Cancer radiation morbidity scoring criteria. 
Results: We retrospectively analyzed 53 patients (pts) with 
pathologically diagnosed NPC, including 37 males and 16 
females; mean age was 52.8 years (range 14-77 years). 
According to the AJCC 2010 staging system 8 pts had II stage, 
30 pts III stage and 15 pts IVA/B stage. At a median follow-up 
of 26 months, 13 pts experienced local regional failure and 
distant metastasis occurred in 11 pts. Reirradiation +/- 
chemotherapy were used as salvage treatment in 6 pts, 
chemotherapy in 2 pts and 2 other pts received surgery (in 1 
pt lymph node dissection and the other pulmonary 
metastasectomy). The 2 years actuarial loco-regional failure–
free survival and disease free survival were 78.9 % and 78.4 




No grade > 4 acute toxicity and no > 3 late toxicity were 
observed. 
Conclusions: IMRT- SIB combined with concurrent 
chemotherapy +/- neoadjuvant CHT resulted in encouraging 
rates of local regional control with acceptable rates of acute 
and late side effects in patients with locoregionally advanced 
NPC.  
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Purpose/Objective: To evaluate the efficacy and toxicity of 
induction chemotherapy (IC) followed by radiochemotherapy 
(RTCT) versus concurrent radiochemotherapy for 
locoregionally advanced nasopharyngeal cancer (NPC).  
Materials and Methods: Patients with locoregionally 
advanced NPC were treated with three cycles of induction 
chemotherapy (IC) with Taxotere (75 mg/m2) plus cisplatin 
(75 mg/m2), plus 5-Fluoruracil (750 mg/m2) followed by full 
doses of IMRT (70 Gy) concurrently with cisplatin 100 
mg/m(2) every 21 days for three cycles (Group A) or to the 
same RTCT regimen alone (Group B). The outcomes of 
patients was evaluated in terms of overall survival (OS), local 
control (LC), and toxicity. 
Results: From July 2007 until December 2013, 45 patients 
were analyzed. Among them, 23 patients received three 
cycles of IC and 22 patients were treated with concomitant 
radiochemotherapy alone. With a median follow-up of 63 
months for the entire group, (range 3-146), 1-ys, 3-ys and 5-
ys Overall Survival were 79%, 58% and 52% for patients 
treated with induction chemotherapy, and 95%, 89% and 81% 
for RTCT alone, respectively (p=0.04). One-year, 3-ys and 5-
ys Disease Free-Survival were 64%, 41% and 19% for patients 
undergone to IC, 88%, 81% and 65% for patients receiving 
RTCT alone (p=0.0020). Patients undergone to 
radiochemotherapy alone had a significantly higher local 
control than patients treated with IC (3-ys LC: 97% vs 40%: p= 
0.0014). The stage affect the final multivariate model for OS 
(p=0.03), and DFS (p=0.0021) and LC (p=0.0086). Acute 
toxicity was similar in both groups. 
Conclusions: Compared with the induction chemotherapy 
group, concurrent chemoradiotherapy alone could 
significantly improve prognosis in terms of overall survival, 
loco-regional failure-free survival, even if patients treated 
with neoadjuvant chemotherapy had a very locally advanced 
disease. However, distant metastatic events still remain a 
problem, and larger and multicenter randomized trials are 
required to assess whether IC followed by RTCT is superior to 
RTCT alone. 
   
EP-1153   
Nasopharyngeal carcinoma treated with intensity-
modulated radiotherapy in a non-endemic area 
H. Letelier1, A. Lozano2, A. Navarro2, R. Mesía3, S. Vásquez3, 
V. Navarro2, M. Mañós4, R. De Blas5, F. Guedea2 
1Universidad de Valparaiso, Oncología Radioterápica, 
Valparaiso, Chile  
2Institut Catala d'Oncologia, Oncología Radioterápica, 
Barcelona, Spain  
3Institut Catala d'Oncologia, Oncología Médica, Barcelona, 
Spain  
4Hospital Universitario de Bellvitge, Otorrinolaringologia, 
Barcelona, Spain  
5Institut Catala d'Oncologia, Física Médica y Protección 
Radiológica, Barcelona, Spain  
 
Purpose/Objective: Despite the numerous retrospective and 
prospective series about IMRT treatment of Nasopharyngeal 
Carcinoma (NPC) in the literature, there is not a clear 
consensus in dose schemes and target volume definitions. 
Furthermore, there are few studies about non-Asiatic 
populations, with small data on European countries. The aim 
of this study is to describe and analyze our results in treating 
all-stages NPC with IMRT-simultaneous integrated boost (SIB), 
in a non-endemic area.  
Materials and Methods: We performed a retrospective 
review of 52 consecutive patients with NPC treated with 
curative intention with IMRT-SIB in our institution between 
